For laboratory research use only - not for human consumption

Compound hub ยท Retatrutide

Retatrutide vs Mounjaro vs Ozempic: what's the difference?

Retatrutide, Mounjaro and Ozempic are three different molecules. The US Ozempic label says semaglutide is a GLP-1 receptor agonist. The US Mounjaro label says tirzepatide is a GIP receptor and GLP-1 receptor agonist. The developer's 2022 paper calls retatrutide a triple glucagon, GIP and GLP-1 receptor agonist. That is a lab description. It does not show effects in people (Coskun et al., 2022). Mounjaro was first registered in Australia on 23 December 2022 (TGA AusPAR, 20 September 2024). It has had US approval since 2022 (US Mounjaro label, DailyMed, 2 September 2026).

Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.

Published 2026-08-18Updated 2026-10-17Written by Form Laboratories research team15 min read

You know the feeling of a meal landing. Twenty minutes in, you stop wanting a second helping. You push the plate away without really deciding to. That is not willpower. It is chemistry. Your gut has already sent messages to your brain, pancreas and liver. They say what arrived and what to do with it.

Three of those messages have names. GLP-1 (glucagon-like peptide-1) is the fullness signal. GIP (glucose-dependent insulinotropic polypeptide) is the meal-and-insulin signal. Glucagon works the other way. It tells your liver to release stored energy when no food is coming in. Your body has used all three for as long as you have lived. This page is part of the retatrutide hub. It covers the three compounds people compare. It also shows which of these signals each label or founding paper names.

  • Guideretatrutide hubRetatrutide research hub: what the compound is, which receptor systems the literature maps it to, what the published trials measured, and how it compares with approved medicines.

Key facts

Key facts for Retatrutide vs Mounjaro vs Ozempic: what's the difference?
Common nameretatrutide
Research codeLY3437943
DeveloperEli Lilly
CAS2381089-83-2
Molecular formulaC221H342N46O68
Molecular weight4731.34 Da
First characterisation paperCoskun et al., Cell Metabolism, 2022
Trial phase as of 2026Phase 3 (ClinicalTrials.gov search for retatrutide, checked 14 October 2026)
Approval as of 2026Not approved by the TGA or a comparable international regulator (TGA safety alert, 14 September 2026)

What is the difference between retatrutide, Mounjaro, and Ozempic?

Retatrutide, Mounjaro, and Ozempic differ in three ways. Each has its own molecule. Each names different hormone receptors. Regulators treat each one differently. The US Ozempic label says semaglutide is a GLP-1 receptor agonist. GLP-1 is the fullness signal. The US Mounjaro label says tirzepatide is a GIP receptor and GLP-1 receptor agonist. GIP is the meal-and-insulin signal. Retatrutide has no label. Its developer's 2022 paper calls it a triple glucagon, GIP and GLP-1 receptor agonist. That is a lab description. It does not show effects in people (Coskun et al., 2022). The TGA says it is in clinical trials. Neither the TGA nor any comparable regulator has approved it (TGA safety alert, 14 September 2026).

Glucagon works differently from GLP-1 and GIP. Your liver listens for it when food has stopped arriving. It tells the liver to release stored energy.

Three columns numbered 1, 2 and 3, holding one, two and three identical dots. Column 1: GLP-1. Column 2: GLP-1 and GIP. Column 3: GLP-1, GIP and glucagon.
Columns run from one signal to three. GLP-1 alone, then GLP-1 with GIP, then all three with glucagon. The third is the developer's 2022 lab description of retatrutide (LY3437943), which does not show effects in people (Coskun et al., 2022).
Molecular Metabolism 2018

Is retatrutide the same as Mounjaro?

Retatrutide is not the same molecule as Mounjaro. Mounjaro is a prescription medicine. It was first put on the Australian Register of Therapeutic Goods on 23 December 2022 (TGA AusPAR, 20 September 2024). It has had initial US approval since 2022 (US Mounjaro label, DailyMed, 2 September 2026). Its active ingredient is tirzepatide. Tirzepatide is a peptide made of 39 amino acids (Coskun et al., 2018). The US Mounjaro label says it is a GIP receptor and GLP-1 receptor agonist. Zepbound is a second US medicine made from the same tirzepatide molecule (US Zepbound label, DailyMed, 2 September 2026). Retatrutide is a separate experimental peptide. It has a different amino-acid sequence and a different research code.

Both compounds share a developer. That is why the names get tangled. A shared developer does not mean a shared molecule. There is one pattern worth noticing. The locks never change. They are the gut-hormone signals your body has used after every meal of your life. Only the key changes.

NEJM 2021SURPASS-2

Is Mounjaro the same molecule as Ozempic?

Mounjaro and Ozempic are different medicines with different active molecules. The US Ozempic label and US Wegovy label list semaglutide as the active ingredient. The Ozempic label says it is a GLP-1 receptor agonist. The US Mounjaro label and US Zepbound label list tirzepatide. The Mounjaro label says it is a GIP receptor and GLP-1 receptor agonist. SURPASS-2 was an open-label trial of 1,879 adults with type 2 diabetes. It ran for 40 weeks. The tirzepatide developer funded it. HbA1c is a three-month blood-sugar marker. It fell by an estimated 2.30 points in the highest tirzepatide trial arm. It fell by 1.86 points with semaglutide. This result is for that group only (Frias et al., 2021).

Those numbers belong to the trial that produced them and nowhere else. SURPASS-2 compared tirzepatide with semaglutide. The people in it had a diagnosis and clinical supervision. The trial looked at one blood marker, chosen before it began. That is a narrow question, answered with care. It is not a league table of molecules.

BMJ Medicine 2026Annals of Internal Medicine 2026BMJ 2026ClinicalTrials.gov NCT06662383

Which is better, retatrutide or Mounjaro?

No study has shown whether retatrutide or Mounjaro is better. The TRIUMPH-5 record had no posted head-to-head result on 14 October 2026. TRIUMPH-5 (NCT06662383) is a registered trial of retatrutide against tirzepatide, the molecule in Mounjaro. It enrols 800 adults. Its primary completion is due in November 2026. Indirect estimates link separate trials through placebo. A 2026 network meta-analysis covered 58 randomised trials. They had 24,214 adults without diabetes. It put weight loss beyond placebo at -22.10% for retatrutide (95% confidence interval -25.60% to -18.60%). For tirzepatide it was -19.28% (-20.39% to -18.16%). The two ranges overlap. The authors note there is little head-to-head evidence (Chen et al., 2026).

Tirzepatide's record is far longer. Mounjaro has had a US label since 2022 (US Mounjaro label, DailyMed, 2 September 2026). The TGA says retatrutide has no approval from the TGA or any comparable regulator (TGA safety alert, 14 September 2026). A 2026 systematic review covered 38 randomised trials. They had 25,816 adults with overweight or obesity and no diabetes. Weight loss beyond placebo was up to -22.1% for retatrutide and -19.0% for tirzepatide. The authors say the trials were too different to combine into one number (Moiz et al., 2026). A 2026 BMJ network meta-analysis covered 262 randomised trials. They had 99,791 adults with overweight or obesity. It rated tirzepatide's one-year weight loss as moderate to high certainty. The loss was 14.9%, against lifestyle change alone. It grouped retatrutide with two other emerging agents. It said they may produce similar or greater reductions. It rated that at very low to low certainty (Nong et al., 2026).

Side effects count in any comparison. A network meta-analysis covered 58 trials in 24,214 adults without diabetes. Its low-certainty evidence suggested more people stopped retatrutide. It suggested mazdutide was easier to tolerate. The abstract gives no count of people who stopped. So the review total does not show how many people that outcome covers (Chen et al., 2026). Asking why retatrutide is better than tirzepatide assumes a result. No head-to-head trial found for this page has reported one. The study findings page lists the registered trials.

Annals of Internal Medicine 2026BMJ 2026ClinicalTrials.gov NCT06260722ClinicalTrials.gov NCT06383390

Is retatrutide better than Ozempic or semaglutide?

No study has shown whether retatrutide is better than Ozempic or semaglutide. The NCT06260722 record had no posted head-to-head result on 14 October 2026. That trial compares retatrutide with semaglutide, the molecule in Ozempic and Wegovy. NCT06260722 is a Phase 3 trial in type 2 diabetes. It has 1,250 adults and is open-label. It reached primary completion on 27 August 2026. It has no results posted (ClinicalTrials.gov, checked 14 October 2026). A 2026 systematic review covered 38 randomised trials in 25,816 adults with overweight or obesity and no diabetes. Weight loss beyond placebo reached up to -22.1% for retatrutide. It reached -14.8% for subcutaneous semaglutide. Those figures come from different trials, people and lengths of time. The authors say the trials were too different to combine. So the figures are not a ranking. Source: Moiz et al., 2026.

Its heart and kidney outcomes trial is NCT06383390. It is active and not recruiting. Its primary completion is estimated for February 2029 (ClinicalTrials.gov, checked 14 October 2026).

Cell Metabolism 2022US Mounjaro label (DailyMed), 2 September 2026US Ozempic label (DailyMed), 10 June 2026Diabetes, Obesity and Metabolism 2026BMJ Medicine 2026

What is retatrutide similar to?

Retatrutide is closest to tirzepatide among the medicines on this page. This is judged by the receptors each one names. The US Mounjaro label says tirzepatide is a GIP receptor and GLP-1 receptor agonist. The developer's 2022 paper calls retatrutide a triple agonist that adds the glucagon receptor. That is a lab description. It does not show effects in people (Coskun et al., 2022). The US Ozempic label says semaglutide is a GLP-1 receptor agonist. A 2026 meta-analysis covered 19 randomised trials in adults with overweight or obesity. It groups four drugs as dual agonists. They act on GLP-1 and glucagon but not GIP. The four are mazdutide, survodutide, cotadutide and efinopegdutide. The abstract gives no count of participants (Amjad et al., 2026). A network meta-analysis also assessed cagrilintide combined with semaglutide (Chen et al., 2026).

Sport Integrity Australia describes retatrutide as a triple receptor agonist. It targets GIP and glucagon receptors as well as GLP-1. It says retatrutide is not on the 2026 World Anti-Doping Agency Prohibited List (checked 14 October 2026). That List has a class called S0. It covers any drug with no current government approval for human use that no other section names (WADA Prohibited List 2026, page 4). So a missing name does not mean permission in sport. Similar names and shared receptors do not make two compounds the same thing. Each one needs its own trial record.

NEJM 2026 (TRIUMPH-1)ClinicalTrials.gov NCT05931367ClinicalTrials.gov NCT05929066

Is retatrutide approved for osteoarthritis, and what have trials studied?

No. Retatrutide is approved for no condition, according to the TGA (TGA safety alert, 14 September 2026). Trials in obesity also studied knee osteoarthritis pain. In TRIUMPH-1, 574 participants had knee osteoarthritis. They recorded WOMAC pain scores. This is a 1 to 10 scale where higher means worse pain. Scores changed by -3.2 to -3.6 across the three retatrutide arms. They changed by -1.9 with placebo. This uses the paper's hybrid estimand. It is a subgroup result from a developer-funded obesity trial. It was read from the abstract. Source: Jastreboff et al., 2026. A dedicated trial, TRIUMPH-4 (NCT05931367), enrolled 445 adults with obesity and knee osteoarthritis. It is completed with no results posted (ClinicalTrials.gov, checked 14 October 2026).

A hybrid estimand is a way of handling events such as stopping treatment. This paper used a hypothetical strategy for events that suggest treatment failure. The paper also reports an intention-to-treat result for the same 574 participants. In that result, the retatrutide arms changed by -3.4 to -4.1. Placebo changed by -2.5. It was read from the abstract and does not describe other participants (Jastreboff et al., 2026). To join the osteoarthritis subgroup, a person needed knee pain for more than 12 weeks. They also needed moderate changes on a knee X-ray (ClinicalTrials.gov NCT05929066).

ClinicalTrials.gov NCT07165028

Is a retatrutide clinical trial recruiting in Australia?

One recruiting retatrutide trial lists Australian sites as of 14 October 2026. It is NCT07165028. It is a Phase 3 trial in adults with a fatty liver disease called MASLD (metabolic dysfunction-associated steatotic liver disease). The adults are at risk of liver outcomes. The sites include Fiona Stanley Hospital in Murdoch. Entry rules include liver fat of 8% or more. They also require no other liver disease (ClinicalTrials.gov, checked 14 October 2026). The other five Australian-site records are completed or active and not recruiting. Each trial sets its own rules. This page is not an invitation to enrol.

The study findings page lists the main registered retatrutide trials. It shows their first-posted dates and status. The registry is where a trial publishes its entry rules and contacts.

  • SourceNCT07165028
  • GuideThe study findings pageWhat published retatrutide trials found on weight, body fat, appetite and side effects, which registered trials are running in Australia, and what the studies do not show.
NEJM 2023NEJM 2022Nature Medicine 2024

Evidence limits

What has the research not shown yet?

Research has not shown whether retatrutide beats tirzepatide or semaglutide. The NCT06662383 and NCT06260722 records had no posted head-to-head results on 14 October 2026. The two figures people put side by side come from separate programmes. The Phase 2 obesity trial ran for 48 weeks with 338 adults. The developer funded it. Its highest arm averaged a 24.2% body-weight reduction. That group average describes that trial only (Jastreboff et al., 2023). SURMOUNT-1 ran for 72 weeks with 2,539 adults without diabetes. The tirzepatide developer funded it. Its highest arm averaged a 20.9% body-weight reduction. That group average also describes that trial only. So the two figures are not comparable (Jastreboff et al., 2022).

It feels natural to line those two percentages up and pick a winner. The evidence cannot support that. The trials are different. The lengths are different: 48 weeks against 72. The people are different, and they joined under different rules. A percentage only means something while it stays attached to the study that produced it.

A third figure often gets quoted alongside them. It comes from a smaller imaging study of 98 adults whose liver fat started at 10% or higher. The authors include developer employees. The top arm averaged an 82.4% drop in liver fat at 24 weeks. That is one study, one trial arm and 24 weeks. It is far too narrow to build a conclusion on (Sanyal et al., 2024). TRIUMPH and TRANSCEND are the Phase 3 programmes that could answer the larger question. None of their results found for this page is a head-to-head comparison.

Two separate horizontal bars with a gap between them and no shared axis, not to scale. First bar: Phase 2, 48 weeks. Second bar: SURMOUNT-1, 72 weeks.
The 48-week Phase 2 trial of retatrutide (Jastreboff et al., 2023) and SURMOUNT-1, the 72-week tirzepatide trial (Jastreboff et al., 2022), come from separate programmes. The bars are not to scale.
ADA briefing, 6 June 2026Jastreboff et al., NEJM, 2026Giblin et al., Diabetes, Obesity and Metabolism, 2025

Which retatrutide percent is the trial result?

TRIUMPH-1 has two public headline figures, so keep each source beside its number. The June 2026 ADA briefing reports 28.3% average weight loss in the highest trial group. The September 2026 journal summary reports 25.0% for that group. Both describe retatrutide over 80 weeks. A third record, the 2025 design paper, sets out the study plan. It does not report those weight results.

ADA means the American Diabetes Association. Its June briefing does not name the method behind that figure. The September paper names a treatment-regimen estimand. That is a rule for which outcomes count in the estimate. Different counting rules might explain the gap. This page has not confirmed that.

The September paper reports a 3.9% average weight loss with placebo, which has no active drug. These are group averages from Jastreboff and colleagues' NEJM paper, checked 17 October 2026. They cannot predict your own result. Giblin and colleagues' 2025 design paper explains the study questions. A plan cannot supply a result, even when another page cites it.

Is research material a substitute for Mounjaro or Ozempic?

Research-use-only material is not a substitute for Mounjaro or Ozempic. Mounjaro and Ozempic are prescription medicines with US labels. They are dispensed and supervised. Laboratory reference material is not those medicines. It is not a cheaper route to them. It is not for human or animal use. A research compound and a medicine can share a molecule. That is a fact of chemistry and nothing more. No retatrutide medicine is approved, according to the TGA (TGA safety alert, 14 September 2026). So there is nothing for laboratory material to stand in for.

Price questions end in the same place. The cost of laboratory material depends on how it is made. That means how long the amino-acid chain is. It means how pure the finished powder is. It also means how much testing sits behind that purity number. It is never a comparison with what a pharmacy charges. This site's retatrutide reference material listing is freeze-dried laboratory stock. Reading laboratory paperwork is a skill of its own. You need to know what a certificate of analysis records. You need to know what a third-party report proves. You need to know how a batch stays traceable. The quality and verification hub walks through it.

Comparison

This table is correct as of 14 October 2026. It has seven rows. Row 1 is the active molecule. Row 2 is the receptors named. Row 3 is approval status. Row 4 is the medicine names for the same molecule. Row 5 is one published trial record for each. Row 6 is registered head-to-head trials. Row 7 is one indirect estimate. The three trials in row 5 differ in group and endpoint. Row 7 links separate trials. It is not a head-to-head result. This table is not a ranking. It is not a guide to use.

Comparison: Retatrutide vs Mounjaro vs Ozempic: what's the difference?
CriterionSemaglutide (Ozempic / Wegovy)Tirzepatide (Mounjaro / Zepbound)Retatrutide
Active moleculesemaglutidetirzepatideretatrutide
Receptor systems in the literatureGLP-1 receptor agonist (US Ozempic label, DailyMed, 10 June 2026).GIP receptor and GLP-1 receptor agonist (US Mounjaro label, DailyMed, 2 September 2026).Triple glucagon, GIP and GLP-1 receptor agonist in the developer's lab description. It does not show effects in people (Coskun et al., 2022).
Approval as of 2026Initial US approval 2017 (US Ozempic label, DailyMed, 10 June 2026).First registered on the ARTG 23 December 2022 (TGA AusPAR, 20 September 2024). Initial US approval 2022 (US Mounjaro label, DailyMed, 2 September 2026).Experimental. In clinical trials. Not approved by the TGA or any comparable regulator (TGA safety alert, 14 September 2026).
Same-molecule medicine namesOzempic, WegovyMounjaro and Zepbound (US Zepbound label, DailyMed, 2 September 2026)None
Representative published recordSURPASS-2 comparator arm (1,879 adults with type 2 diabetes, open-label): HbA1c -1.86 points over 40 weeks. This is for that trial group only, not a ranking across trials (Frias et al., 2021).SURMOUNT-1 (2,539 adults without diabetes): -20.9% mean body-weight change in the highest trial arm over 72 weeks. This is for that trial group only. It cannot be compared with other trials (Jastreboff et al., 2022).Phase 2 (338 adults with obesity, developer-funded): -24.2% mean body-weight change in the highest trial arm over 48 weeks. This is for that trial group only. It cannot be compared with other trials (Jastreboff et al., 2023).
Registered head-to-head trial with retatrutideNCT06260722: type 2 diabetes, 1,250 adults, open-label. No results posted (ClinicalTrials.gov, 14 October 2026).TRIUMPH-5, NCT06662383: obesity, 800 adults. No results posted (ClinicalTrials.gov, 14 October 2026).Both trials above
Indirect estimate: weight loss beyond placebo in adults without diabetesUp to -14.8% for subcutaneous semaglutide, in a systematic review of 38 randomised trials. They covered 25,816 adults with overweight or obesity and no diabetes. The trials were too different to combine, so this is not a ranking (Moiz et al., 2026).Up to -19.0% for tirzepatide, from the same 2026 review of 38 trials. The trials were too different to combine, so this is not a ranking (Moiz et al., 2026).Up to -22.1% for retatrutide, from the same 2026 review of 38 trials. The trials were too different to combine, so this is not a ranking (Moiz et al., 2026).

FAQ

How is retatrutide different from Ozempic or Mounjaro?

Retatrutide differs from Ozempic and Mounjaro in its molecule and its receptors. The US Ozempic label says semaglutide (Ozempic / Wegovy) is a GLP-1 receptor agonist. The US Mounjaro label says tirzepatide (Mounjaro / Zepbound) is a GIP receptor and GLP-1 receptor agonist. The developer's 2022 paper calls retatrutide a triple glucagon, GIP and GLP-1 receptor agonist. That is a lab description. It does not show effects in people (Coskun et al., 2022). Ozempic and Mounjaro have US labels. The TGA says retatrutide has no approval from the TGA or any comparable regulator (TGA safety alert, 14 September 2026).

Is retatrutide the same as Mounjaro?

No. Mounjaro contains tirzepatide, a 39-amino-acid peptide. Retatrutide is a different peptide with a different sequence. A shared developer does not make two compounds the same thing.

Is Zepbound the same as Mounjaro?

Zepbound and Mounjaro are two medicine names for the same molecule, tirzepatide. The US Mounjaro label and the US Zepbound label both list it as the active ingredient (DailyMed, 2 September 2026). Neither name refers to retatrutide.

Is retatrutide better than Mounjaro?

No study has shown whether retatrutide is better than Mounjaro. The NCT06662383 record had no posted head-to-head result on 14 October 2026. That trial compares retatrutide with tirzepatide, the molecule in Mounjaro. The Phase 2 obesity trial ran for 48 weeks with 338 adults. Its highest arm averaged a 24.2% body-weight reduction. That group average is for that developer-funded trial only (Jastreboff et al., 2023). The SURMOUNT-1 trial ran for 72 weeks with 2,539 adults without diabetes. Its highest arm averaged a 20.9% body-weight reduction. That group average is for that developer-funded trial only (Jastreboff et al., 2022). These separate trials do not show which molecule is better.

Is research retatrutide cheaper than Mounjaro?

Research-use-only material is not a cheaper version of Mounjaro or of any prescription medicine. The cost of laboratory reference material depends on chain length, purity and testing. It is supplied for laboratory work. It is not a medicine.

Is retatrutide better than semaglutide?

No study has shown whether retatrutide is better than semaglutide. The NCT06260722 record had no posted head-to-head result on 14 October 2026. The registered retatrutide-against-semaglutide trial, NCT06260722 in type 2 diabetes, has no results posted as of 14 October 2026. A 2026 systematic review covered 38 randomised trials in 25,816 adults with overweight or obesity and no diabetes. It put weight loss beyond placebo at up to -22.1% for retatrutide and -14.8% for subcutaneous semaglutide. These came from separate trials. The authors say the trials were too different to combine (Moiz et al., 2026).

Why is retatrutide better than tirzepatide?

No head-to-head study has shown that retatrutide is better than tirzepatide. The NCT06662383 record had no posted head-to-head result on 14 October 2026. A network meta-analysis covered 58 randomised trials in 24,214 adults without diabetes. The confidence interval for retatrutide overlapped with tirzepatide's. This is an indirect comparison, and there is little head-to-head evidence (Chen et al., 2026). TRIUMPH-5 (NCT06662383) is the registered head-to-head trial.

How long does it take for retatrutide to kick in?

The Phase 1 study had 45 healthy adults. The group-median time to peak blood level ranged from 12 to 72 hours after a single exposure. That result is for that small study only (Coskun et al., 2022). Trials measured weight over weeks and months. In the Phase 2 obesity trial of 338 adults, the highest arm was at -17.5% by week 24. That result is for that trial group (Jastreboff et al., 2023). The pharmacokinetics page separates peak levels from effects.

How long does it take for retatrutide to go out of your system?

Three papers were checked for this page on 14 October 2026: Coskun 2022, Urva 2022 and Carneiro 2026. None reported a complete-clearance time. The half-life was about six days in 72 adults with type 2 diabetes. That was a small early-phase trial (Urva et al., 2022). A small lab study covered four adults who used retatrutide outside a trial. Intact retatrutide stayed detectable in plasma for about 56 days after the first exposure. That is a detection result, not a clearance time. The abstract does not name where the product came from (Carneiro et al., 2026).

Citations

14 sources
  1. Coskun T et al. Cell Metabolism. 2022;34(9):1234-1247.e9.
    doi:10.1016/j.cmet.2022.07.013

  2. Coskun T et al. Molecular Metabolism. 2018;18:3-14.
    doi:10.1016/j.molmet.2018.09.009

  3. Frias JP et al. New England Journal of Medicine. 2021;385(6):503-515.
    doi:10.1056/NEJMoa2107519

  4. Jastreboff AM et al. New England Journal of Medicine. 2022;387(3):205-216.
    doi:10.1056/NEJMoa2206038

  5. Jastreboff AM et al. New England Journal of Medicine. 2023.
    doi:10.1056/NEJMoa2301972

  6. Sanyal AJ et al. Nature Medicine. 2024;30:2037-2048.
    doi:10.1038/s41591-024-03018-2

  7. Jastreboff AM et al. New England Journal of Medicine. 2026, online 29 September (TRIUMPH-1).
    doi:10.1056/NEJMoa2604169

  8. Chen D et al. BMJ Medicine. 2026;5(1):e003026.
    doi:10.1136/bmjmed-2026-003026

  9. Moiz A et al. Annals of Internal Medicine. 2026, online 1 September.
    doi:10.7326/ANNALS-25-05519

  10. Nong K et al. BMJ. 2026;394:e372161.
    doi:10.1136/bmj-2026-372161

  11. Amjad MM et al. Diabetes, Obesity and Metabolism. 2026, online 29 September.
    doi:10.1111/dom.71400

  12. Urva S et al. The Lancet. 2022;400(10366):1869-1881.
    doi:10.1016/S0140-6736(22)02033-5

  13. Carneiro GRA et al. Rapid Communications in Mass Spectrometry. 2026;40(23):e70179.
    doi:10.1002/rcm.70179

  14. Giblin K et al. Diabetes, Obesity and Metabolism. 2025; TRIUMPH trial design; published 15 October.
    doi:10.1111/dom.70209

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Continue

Retatrutide reference material

Research use only. Not for human or animal use.

Read the retatrutide research guide

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease